NTRC publishes target residence time-guided optimization of TTK inhibitors
This week, NTRC published results from its TTK (Mps1) drug discovery programme in the Journal of Molecular Biology.
Read more
Pluriomics BV partners with Pivot Park Screening Centre
Pluriomics partners with Pivot Park Screening Centre for Cardiovascular drug discovery services.
Read more
Synaffix Secures End-to-End Patent Protection of Its ADC Technology Platform as Its HydraSpace™ Patent Grants in the United States
Synaffix announced that a key patent covering its HydraSpace™ spacer technology has been granted by the US Patent and Trademark Office.
Read more
Lead Pharma Achieves Second Milestone for Development of Autoimmune Diseases Treatments in Sanofi Collaboration
Lead Pharma announced that it has achieved a second milestone under its research collaboration with Sanofi.
Read more
Rob Prins nieuwe voorzitter Raad van Bestuur Pivot Park
Rob Prins vervangt per 1 april Jan Pelle als voorzitter van de Raad van Bestuur van Pivot Park.
Read more
Enterprise System Partners and TraceLink Form Strategic Alliance
Enterprise System Partners announced it has established a strategic partnership with TraceLink.
Read more
New study in Oncotarget shows that stable aneuploid cells are more sensitive to TTK inhibition than chromosomally unstable cell lines
Stable aneuploid tumor cells are more sensitive to small molecule inhibitors of TTK than chromosome instable cells.
Read more
New at Pivot Park: PerkinElmer OneSource
Since mid-February OneSource is a new occupant in the Pivot Park community.
Read more
Regenerative medicine crossing borders
Osteo-Pharma will take part in the five-year project focusing on taking steps towards a bioengineered joint.
Read more